Leqvio Employer + ICHRA Coverage Navigation: How to Get Inclisiran Covered in 2026

What Leqvio Is and Why Coverage Is Complicated

Leqvio (inclisiran) earned FDA approval on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab, inclisiran works through RNA interference, silencing PCSK9 messenger RNA inside hepatocytes rather than blocking the protein in circulation [2].

The clinical payoff is meaningful. In ORION-10 (N=1,561), inclisiran 284 mg reduced LDL-C by a time-averaged 52 percent versus placebo at day 510 (P<0.0001) [3]. The twice-yearly dosing after the initial loading sequence removes the every-two-week injection burden that caused adherence problems with earlier PCSK9 agents.

Coverage, however, does not follow automatically from clinical efficacy. Leqvio carries a wholesale acquisition cost of roughly $3,500 per dose. Payers classify it as a specialty-tier biologic, and most commercial plans layer on prior authorization requirements, step therapy mandates, and, increasingly, site-of-care restrictions that limit reimbursement to physician offices rather than infusion centers or home administration.

Why Payers Resist Approval

Plans typically demand proof that a patient has tried and failed or cannot tolerate at least one or two high-intensity statins before approving Leqvio. Some also require a documented trial of ezetimibe. The ACC/AHA 2022 guideline on nonstatin therapies endorses this stepwise approach, noting that ezetimibe adds roughly 13 to 20 percent additional LDL-C reduction at low cost before a PCSK9 inhibitor is warranted [4].

The Specialty Pharmacy Layer

Once approved, Leqvio is typically dispensed through a specialty pharmacy or administered in a physician office and billed under the medical benefit (CPT code 96372 for the injection). Whether your plan routes the drug through pharmacy or medical benefits changes which deductible and out-of-pocket maximum applies, which matters enormously for patients in high-deductible health plans (HDHPs) linked to ICHRAs.

Employer-Sponsored Plans: What to Expect in 2026

Most large self-insured employer plans cover Leqvio on Tier 4 or Tier 5 specialty formulary positions. A 2024 IQVIA analysis found that roughly 78 percent of commercial lives had some form of PCSK9 inhibitor coverage, but prior authorization approval rates for inclisiran specifically hovered near 62 percent on the first submission [5].

Prior Authorization Checklist

Before your physician submits a PA request for Leqvio, gather the following documentation. Missing even one item typically adds two to four weeks to the review cycle:

• Current LDL-C level (ideally two readings <3 months apart)
• Confirmed ASCVD diagnosis (ICD-10: I25.10, I63.x, or I74.x) or genetic HeFH documentation
• Evidence of maximally tolerated statin therapy (drug name, dose, duration)
• Evidence of ezetimibe trial if required by your specific plan
• Prescriber attestation of cardiovascular risk category
• Most recent lipid panel showing inadequate LDL-C control on current therapy

The American College of Cardiology's 2023 Expert Consensus Decision Pathway states: "Clinicians should document the specific reasons statin therapy is not tolerable or is maximally tolerated, and note the patient's baseline and current LDL-C values, to support prior authorization requests for nonstatin therapies" [6].

Step Therapy Appeals

If the plan denies the PA citing incomplete step therapy, most states now have step therapy override laws requiring plans to grant an exception when step therapy is clinically contraindicated or when the patient already failed the required therapy. As of 2024, 41 states plus the District of Columbia had enacted step therapy protections of some form. The prescribing physician should submit a peer-to-peer review request within 72 hours of denial; approval rates at peer-to-peer review for PCSK9 inhibitors are substantially higher than initial electronic PA submissions [7].

Medical vs. Pharmacy Benefit Routing

Ask your benefits coordinator whether Leqvio will be covered under the medical benefit (buy-and-bill at the physician office) or the pharmacy benefit (specialty pharmacy dispensing). Buy-and-bill routes the cost through your medical deductible and typically allows physician office administration. Pharmacy-benefit routing pulls from the pharmacy deductible, which may be separate. In HDHPs, the pharmacy deductible can be as high as $1,500 individually before any coverage kicks in, creating a meaningful gap for patients in the loading phase.

ICHRA Coverage Navigation for Leqvio

An Individual Coverage HRA (ICHRA) is an employer-funded, tax-advantaged account that reimburses employees for individual health insurance premiums and, depending on plan design, qualified medical expenses [8]. ICHRAs were authorized by final IRS and DOL rule on June 13, 2019, effective plan years beginning January 1, 2020.

For Leqvio access, ICHRA creates a two-step problem. First, the underlying individual market plan (purchased on-exchange or off-exchange) must include Leqvio on its formulary. Second, any unreimbursed out-of-pocket costs may be reimbursed from the ICHRA balance, subject to the plan design the employer chose.

Step 1: Confirm Your Individual Plan's Formulary

Before open enrollment, check the Summary of Benefits and Coverage (SBC) and the actual formulary of any individual plan you are considering. CMS requires all qualified health plans (QHPs) on HealthCare.gov to cover at least one drug in every United States Pharmacopeia (USP) protected class, but PCSK9 inhibitors do not fall into a protected class. This means off-exchange plans in particular may simply exclude inclisiran.

Use HealthCare.gov's plan comparison tool and filter by drug coverage. Search for "inclisiran" or "Leqvio" in the formulary lookup. If your state runs its own exchange, the equivalent tool will be on your state marketplace website.

Step 2: Use ICHRA Funds for Remaining Out-of-Pocket Costs

Once you select a plan with Leqvio coverage, your ICHRA balance can typically reimburse:

• Your monthly premium (always reimbursable with an ICHRA)
• Copayments and coinsurance for covered drugs and office visits
• Deductible payments for covered services

ICHRA reimbursements are tax-free to the employee when used for qualified medical expenses as defined in IRC Section 213(d) [9]. Prescription drugs meeting that definition (which inclisiran does) are eligible expenses. This means a $300 monthly ICHRA contribution from your employer can offset a meaningful share of specialty-tier cost-sharing.

Step 3: Stack the Novartis Copay Card

ICHRA participants purchasing individual market insurance are generally eligible for manufacturer copay assistance cards, unlike Medicare or Medicaid beneficiaries. Novartis's Leqvio copay card program (branded as the "Leqvio $0 Copay Offer" through the Novartis Patient Assistance Foundation) can bring commercial out-of-pocket cost to $0 per injection for eligible commercially insured patients. The program website is updated periodically; confirm current terms at novartis.com or through the prescribing physician's office before relying on any specific dollar figure.

Stacking ICHRA reimbursement with the Novartis copay card is permissible as long as no portion of the same expense is double-counted. The copay card reduces the amount owed to the pharmacy or physician; the ICHRA can then reimburse any remaining balance. If the copay card brings the cost to zero, there is no remaining expense for the ICHRA to reimburse.

How to Get Leqvio Cheaper: Every Available Lever in 2026

Lever 1: Novartis Patient Support Programs

Novartis operates the "Leqvio Together" patient support program in the United States. Key components include benefits investigation support (staff will call your insurer on your behalf), prior authorization assistance, appeal support, and the copay card for commercially insured patients. For uninsured or underinsured patients who meet income criteria, the Novartis Patient Assistance Foundation may provide Leqvio at no cost.

Lever 2: Specialty Pharmacy Negotiation

Because Leqvio is a specialty drug, your plan's specialty pharmacy (CVS Specialty, Accredo, Optum Specialty, etc.) may have a contracted rate that differs from the WAC. Ask your specialty pharmacy coordinator for the plan-negotiated rate before your first fill. The actual cost to a payer is typically 20 to 40 percent below WAC after rebates, but that rebate does not always flow through to the patient's cost-sharing calculation in non-integrated plans.

Lever 3: Site-of-Care Optimization

Some payers cover Leqvio at a lower patient cost-sharing rate when administered in a physician office under the medical benefit rather than at a hospital outpatient department. A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that site-of-care shifting from hospital outpatient to physician office for specialty injectables reduced patient out-of-pocket costs by an average of 31 percent [10]. Ask your cardiologist or primary care physician whether in-office administration is available.

Lever 4: 340B Program Access

Patients receiving care at qualifying federally qualified health centers (FQHCs), disproportionate-share hospitals, or other 340B-covered entities may access Leqvio at 340B pricing, which can be substantially below commercial WAC. Eligibility is institutional (the prescribing entity must participate in 340B), not individual. The Health Resources and Services Administration (HRSA) maintains a searchable database of 340B-covered entities at hrsa.gov [11].

Lever 5: HSA and FSA Use

Leqvio is a prescription medication and qualifies as a medical expense under IRC Section 213(d). Patients with a health savings account (HSA) or flexible spending account (FSA) can use pre-tax dollars to pay any remaining out-of-pocket cost not covered by insurance or a copay card. For a patient in the 22 percent federal tax bracket, using HSA/FSA funds effectively reduces a $200 out-of-pocket cost to approximately $156 in after-tax terms. HSA contributions in 2026 are capped at $4,300 for self-only coverage and $8,550 for family coverage under IRS Rev. Proc. 2025-19 [12].

Prior Authorization Appeal Strategy

Roughly one in three initial PA requests for PCSK9 inhibitors is denied on the first submission, according to a 2022 JAMA study examining prior authorization outcomes for cardiovascular medications [13]. The denial is not the end of the road. A structured appeal process works.

First-Level Appeal

Submit within 30 days of the denial notice. Include:

• The specific denial reason (step therapy incomplete, not on formulary, not medically necessary)
• A detailed letter of medical necessity from the prescribing physician citing the patient's ASCVD or HeFH diagnosis, LDL-C values, statin trial history, and relevant ACC/AHA guideline language
• Peer-reviewed literature supporting inclisiran's efficacy, such as the ORION-10 trial publication in the New England England Journal of Medicine [3]

Peer-to-Peer Review

Request a peer-to-peer telephone review between your cardiologist and the plan's medical director. This step alone reverses approximately 40 to 60 percent of PCSK9 inhibitor denials in published analyses [7]. Schedule it within 72 hours of denial.

External Independent Review

If the internal appeal fails, most states require payers to offer external independent review for medical necessity denials. The external reviewer is not employed by the insurer. Approval rates in external review for specialty cardiovascular drugs are generally higher than internal appeal outcomes.

State Insurance Commissioner Complaint

Filing a formal complaint with the state insurance commissioner creates a regulatory record and typically triggers a prompt internal re-review by the plan's compliance team. This step is underused by patients and adds no cost.

Clinical Context: Why Aggressive LDL-C Lowering Matters

The clinical rationale for fighting this coverage battle is grounded in large outcomes data. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15 percent relative risk reduction versus placebo (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median 2.2 years in statin-treated ASCVD patients [14]. Inclisiran's outcomes trial (ORION-4, N=15,000+) is fully enrolled with results anticipated; the biological plausibility for cardiovascular event reduction is strong given its degree of LDL-C lowering.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "For patients with LDL-C levels remaining ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor may be considered" [15]. Inclisiran is the only approved siRNA-based PCSK9 inhibitor and the only one offering twice-yearly dosing after loading, a practical advantage for adherence in the real world.

A 2024 meta-analysis in The Lancet (pooling ORION-10, ORION-9, and ORION-11, total N=3,660) found that inclisiran reduced time-averaged LDL-C by 50.7 percent versus placebo across the three trials, with a safety profile comparable to placebo for serious adverse events (incidence rate ratio 0.99; 95% CI 0.87 to 1.13) [16].

HealthRX Decision Framework: ICHRA + Leqvio Access in Four Steps

The following four-step framework is designed for HR benefits coordinators and patients navigating ICHRA for the first time with a specialty cardiovascular drug:

Step A. Pre-enrollment formulary audit. Before selecting an individual market plan during open enrollment, search the plan's drug formulary for "inclisiran" and confirm the tier, prior authorization requirements, quantity limits, and specialty pharmacy restrictions. Do this for every plan option, not just the cheapest premium.

Step B. ICHRA contribution adequacy check. Calculate whether the employer's ICHRA contribution, combined with the Novartis copay program, will cover the plan premium plus anticipated specialty cost-sharing. For 2026, a $500/month ICHRA contribution provides meaningful premium offset in most markets; anything below $200/month may leave significant exposure for specialty drug cost-sharing after the deductible.

Step C. PA submission with complete documentation. Use the checklist above. Submit via the prescriber's EHR-integrated PA tool and simultaneously call the insurer's specialty pharmacy PA line to flag the submission as urgent for a patient with established ASCVD.

Step D. Copay card enrollment on day of first injection. Enroll in the Novartis Leqvio Together program before the first dose is administered, not after. Retroactive copay card application is possible in some cases but is not guaranteed, and the enrollment process takes two to three business days.